e 4031 has been researched along with Adenocarcinoma, Basal Cell in 2 studies
E 4031: class III anti-arrhythmia agent; structure given in UD
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dolderer, JH | 1 |
| Schuldes, H | 1 |
| Bockhorn, H | 1 |
| Altmannsberger, M | 1 |
| Lambers, C | 1 |
| von Zabern, D | 1 |
| Jonas, D | 1 |
| Schwegler, H | 1 |
| Linke, R | 1 |
| Schröder, UH | 1 |
| Roy, J | 1 |
| Vantol, B | 1 |
| Cowley, EA | 1 |
| Blay, J | 1 |
| Linsdell, P | 1 |
2 other studies available for e 4031 and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
HERG1 gene expression as a specific tumor marker in colorectal tissues.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Line, Tum | 2010 |
Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.
Topics: Adenocarcinoma; Anti-Allergic Agents; Anti-Arrhythmia Agents; Astemizole; Breast Neoplasms; Cell Pro | 2008 |